Alirocumab and evolocumab are fully human monoclonal antibodies that inhibit proprotein convertase subtilisinekexin type 9 [iPCSK9]. These agents reduce the risk of cardiovascular and limb events in statin-treated subjects [1,2]. However, the effect of iPCSK9 on arterial stiffness has not yet been reported. In this report, we present data from two patients who experienced an impressive improvement in carotid-femoral pulse wave velocity [cfPWV] after short-term treatment with iPCSK9
Improvement in arterial stiffness after short-term treatment with PCSK9 inhibitors / Cicero A, Toth PP, Fogacci F, Virdis A, Borghi C. - In: NMCD. NUTRITION METABOLISM AND CARDIOVASCULAR DISEASES. - ISSN 0939-4753. - STAMPA. - 29:5(2019), pp. 527-529. [10.1016/j.numecd.2019.01.010]
Improvement in arterial stiffness after short-term treatment with PCSK9 inhibitors.
Cicero A;Borghi C
2019
Abstract
Alirocumab and evolocumab are fully human monoclonal antibodies that inhibit proprotein convertase subtilisinekexin type 9 [iPCSK9]. These agents reduce the risk of cardiovascular and limb events in statin-treated subjects [1,2]. However, the effect of iPCSK9 on arterial stiffness has not yet been reported. In this report, we present data from two patients who experienced an impressive improvement in carotid-femoral pulse wave velocity [cfPWV] after short-term treatment with iPCSK9I documenti in IRIS sono protetti da copyright e tutti i diritti sono riservati, salvo diversa indicazione.
